|
EQS-News: Medios AG / Key word(s): Half Year Report/Half Year Results Medios AG: achieves further growth in the first half of 2023 and expects strong third quarter 14.08.2023 / 07:53 CET/CEST The issuer is solely responsible for the content of this announcement. Press release Medios AG achieves further growth in the first half of 2023 and expects strong third quarter
Berlin, August 14, 2023 – Medios AG (“Medios”), the leading provider of Specialty Pharma Solutions in Germany, has continued its growth course in the first half of 2023 and expects a strong third quarter. Accordingly, the company confirms its forecast for the full year. Revenue increased by 7.7% year-on-year to €853.5 million in the period from January to June 2023 (previous year: €792.2 million); both operating segments achieved revenue growth. EBITDA pre1 increased by 1.9% to €29.0 million (previous year: €28.5 million) despite ongoing global uncertainties and regulatory adjustments. Consequently, the EBITDA pre1 margin in the first half of 2023 of 3.4% was slightly below the level of the prior-year period (previous year: 3.6%). Matthias Gaertner, CEO of Medios AG: “The first half of the year was again successful for Medios. We were able to continue implementing our growth strategy as planned and are ideally positioned for a strong second half of 2023. Here, the inventory management already initiated in the first half of the year will have a positive impact, particularly in the third quarter of 2023. Significant effects are already reflected in a strong business performance in July. We therefore remain on track to achieve our targets for the full year 2023 as well as our mid-term goals.” The revenue growth of the Medios Group in the first half of 2023 was attributable to continued organic growth in both operating segments. In addition, Blisterzentrum Baden-Württemberg GmbH (“bbw”), which has been included in the consolidated financial statements since January 2023, contributed to the revenue growth. This transaction also included an extensive cooperation agreement to take over the compounding volumes of Apotheken für Spezialversorgungen OHG (“AfS”), which Medios successfully started to integrate in the first half of 2023. The increase in EBITDA pre1 was slowed by regulatory price changes (auxiliary tax; “Hilfstaxe”) since September 2022. Due to expected inflation-related price adjustments in the area of pharmaceutical supply, Medios built-up inventories in the first half of 2023. Particularly this measure resulted in a cash flow from operating activities of € –75.2 million in the first half of 2023 (previous year: €9.9 million). For the second half of 2023, Medios expects corresponding positive effects on the cash flow due to the reduction of inventories. In the first half of 2023, Medios was again active in strategic portfolio management: With the acquisition of bbw and the subsequent sale of Kölsche Blister GmbH, the Company is now concentrating its blister business at one location in southern Germany. In addition, Medios gained further compounding volumes through the agreement concluded with AfS. Revenue growth in both operating segments In the first half of 2023, the Pharmaceutical Supply segment achieved an increase in revenue of 7.6% to €734.1 million (previous year: € 682.5 million). The segment’s EBITDA pre1 increased by 13.9 % to €19.9 million (previous year: €17.5 million). Of this, €23.1 million in revenue and €1.0 million in EBITDA pre were attributable to bbw. The Patient-Specific Therapies segment generated revenue of €118.9 million in the first half of 2023, up 8.6% on the prior-year figure (previous year: €109.5 million). EBITDA pre1 of the segment decreased by 5.5% to €12.5 million (previous year: €13.2 million). The decline was mainly due to regulatory price reductions (auxiliary tax reductions; “Hilfstaxenabschläge”) for certain active ingredients. On May 31, 2023, the Supervisory Board of Medios AG had resolved to extend the existing Executive Board contract of Falk Neukirch (Chief Financial Officer) until April 30, 2026. Falk Neukirch has been a member of the Executive Board since October 1, 2021 and is responsible for the Finance department. Positive outlook for the 2023 financial year confirmed Medios is very confident about its business development in the second half of the year and confirms its full year forecast for 2023 published on February 22, 2023. Accordingly, the Company expects consolidated revenue for the 2023 financial year to be in the range of €1.6 – 1.8 billion, representing a year-on-year increase of up to 11.8%. EBITDA pre1 is expected to be in the range of €56 – 63 million – a growth rate of up to 14.8% year-on-year. In the mid-term, Medios is targeting consolidated revenue of over €2 billion and an EBITDA-pre1-margin in the mid-single-digit range.
Important dates for Medios AG in 2023 financial year: September 8: Capital Markets Conference – Barcelona The half-year financial report of Medios AG as of June 30, 2023, is available for download on the Investor Relations website. 1 EBITDA is defined as consolidated earnings before interest, taxes, depreciation and amortization. EBITDA pre is adjusted for special charges for stock options and expenses for M&A activities as well as from 2023 additionally for one-time performance-based payments for the acquisition of compounding volumes. ——————- About Medios AG Medios AG is the leading provider of Specialty Pharma Solutions in Germany. As a competence partner and expert, Medios covers all relevant aspects of the supply chain in this field: from pharmaceutical supply to the manufacture of patient-specific therapies including blistering. The focus is on optimal patient care via specialized pharmacies. Medios AG is Germany’s first listed Specialty Pharma company. The shares (ISIN: DE000A1MMCC8) are listed on the Regulated Market of the Frankfurt Stock Exchange (Prime Standard). Contact Claudia Nickolaus Anna Höffken Disclaimer This communication contains forward-looking statements that are subject to certain risks and uncertainties. Future results could differ materially from those currently anticipated as a result of various risk factors and uncertainties, including, but not limited to, changes in business, economic and competitive conditions, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing.
14.08.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Surveillance Still Not an Option for Many With Subsegmental Pulmonary Embolism
Only a narrow pool of outpatients with acute subsegmental pulmonary embolism (PE) may be candidates for structured surveillance without anticoagulation based on current guideline restrictions,
August 4, 2023